Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy
Sponsor: MultiVir, Inc.
A PHASE2 clinical study on Lymphoma and Solid Tumor, this trial is ongoing. The trial is conducted by MultiVir, Inc. and has accumulated 10 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE2
-
Apr 2019 — Mar 2020 [monthly]
Recruiting PHASE2
-
Oct 2018 — Apr 2019 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MultiVir, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .